Literature DB >> 2202080

Aminoglycoside-induced ototoxicity.

P J Govaerts1, J Claes, P H van de Heyning, P G Jorens, J Marquet, M E De Broe.   

Abstract

One of the major side effects of aminoglycoside antibiotics (AG) is ototoxicity. The authors review the literature revealing many controversies on every aspect of this side-effect. Although epidemiological studies have to face the problem of reliable evaluation techniques, the incidence of cochleo- and vestibulotoxic side-effects has been estimated at 7.5% for each. Netilmicin appears to be less ototoxic. No definite risk factors can be proposed, although age, length of therapy, bacteremia, fever, liver and renal dysfunction are probably very important parameters. Most pathological changes at the cochlear level follow a clear spatial sequence, showing unspecific, degenerative lesions, involving every structure of the cochlea. This makes it impossible to draw etiopathological conclusions. Recent pharmacokinetic studies have rejected the 'accumulation theory' of AGs in perilymph, while also in endolymph no accumulation can be found. Only a few data are available on inner ear tissue levels. Among the different pharmacodynamic hypotheses on the action of AGs, binding of the drug to acidic glycosaminoglycans in the stria vascularis, and interference by the drug with phosphoinositide metabolism in the hair cells seem to be of major importance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2202080     DOI: 10.1016/0378-4274(90)90033-i

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  19 in total

Review 1.  Drug-induced tinnitus and other hearing disorders.

Authors:  H Seligmann; L Podoshin; J Ben-David; M Fradis; M Goldsher
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Effect of isepamicin dosing scheme on concentration in cochlear tissue.

Authors:  P J Govaerts; J Claes; P H Van de Heyning; M P Derde; L Kaufman; J F Marquet; M E De Broe
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 3.  Chemical exposure and hearing loss.

Authors:  Pierre Campo; Thais C Morata; OiSaeng Hong
Journal:  Dis Mon       Date:  2013-04       Impact factor: 3.800

4.  Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.

Authors:  Michael Mulheran; Pauline Hyman-Taylor; Kelvin H-V Tan; Sarah Lewis; David Stableforth; Alan Knox; Alan Smyth
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 5.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

6.  Gentamicin induced ototoxicity during treatment of enterococcal endocarditis: resolution with substitution by netilmicin.

Authors:  J E East; J E Foweraker; F D Murgatroyd
Journal:  Heart       Date:  2005-05       Impact factor: 5.994

7.  Infection-mediated vasoactive peptides modulate cochlear uptake of fluorescent gentamicin.

Authors:  Ja-Won Koo; Qi Wang; Peter S Steyger
Journal:  Audiol Neurootol       Date:  2010-12-30       Impact factor: 1.854

8.  Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration.

Authors:  Sofia Lyford-Pike; Casey Vogelheim; Eugene Chu; Charles C Della Santina; John P Carey
Journal:  J Assoc Res Otolaryngol       Date:  2007-09-25

Review 9.  PharmGKB summary: very important pharmacogene information for MT-RNR1.

Authors:  Julia M Barbarino; Tracy L McGregor; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-12       Impact factor: 2.089

10.  Lack of ciprofloxacin ototoxicity after repeated ototopical application.

Authors:  J Claes; P J Govaerts; P H Van de Heyning; S Peeters
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.